Teva Pharma (TEVA) Tops Q2 EPS by 12c, Offers Guidance
Get Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharma (NYSE: TEVA) reported Q2 EPS of $0.68, $0.12 better than the analyst estimate of $0.56. Revenue for the quarter came in at $3.8 billion versus the consensus estimate of $3.78 billion.
GUIDANCE:
Teva Pharma sees FY2022 EPS of $2.40-$2.60. Teva Pharma sees FY2022 revenue of $15-15.6 billion.
For earnings history and earnings-related data on Teva Pharma (TEVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- The First Of Long Island (FLIC) Misses Q1 EPS by 3c
- Northeast Community Bancorp, Inc. (NECB) Tops Q1 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!